Saxagliptin: a guide to its use in type 2 diabetes mellitus
- 102 Downloads
Oral saxagliptin (Onglyza®), a potent, selective dipeptidyl pepitase-4 inhibitor, is a useful option to improve glycaemic control in treatment-naïve and treatment-experienced patients with type 2 diabetes mellitus. The efficacy of saxagliptin 2.5 or 5 mg once daily as initial therapy and add-on therapy to various baseline antihyperglycaemic agents has been demonstrated in a number of clinical trials in patients with type 2 diabetes, including those with renal impairment. Saxagliptin is generally well tolerated, does not increase the risk of hypoglycaemia or cardiovascular outcomes relative to placebo or active comparators, and is generally weight neutral.
The manuscript was reviewed by: D.S.H. Bell, Division of Endocrinology, University of Alabama Medical School, Southside Endocrinology, Birmingham, AL, USA; G. Dimitriadis, 2nd Department of Internal Medicine, Research Institute and Diabetes Center, University of Athens Medical School, Attikon University Hospital, Athens, Greece; J.G. Eriksson, Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland.
This article was updated from Drugs 2012;72(2):229-48 . The preparation of these reviews was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.
- 6.Onglyza® (saxagliptin) tablets, for oral use: US prescribing information. Princeton: Bristol-Myers Squibb Company; 2013.Google Scholar
- 7.Onglyza® (saxagliptin) coated tablets: Brazilian prescribing information [in Portugeuse]. São Paulo: Bristol-Myers Squibb Farmacêutica S.A.; 2013.Google Scholar
- 8.Wang A, Dorso C, Kopcho L, et al. Implications of the prolonged dissociation rate of saxagliptin, a highly potent and selective DPP4 inhibitor, on plasma DPP measurements [abstract no. 2088-PO]. Diabetes. 2008;57(Suppl. 1):A576–7.Google Scholar
- 12.Kirby M, Yu DMT, O’Connor SP, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond). 2010;18(1):31–41.Google Scholar
- 15.Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–22.PubMedCrossRefGoogle Scholar
- 17.Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–406.PubMedCentralPubMedCrossRefGoogle Scholar
- 23.Ravichandran S, DeFronzo R, Garber AJ, et al. Once-daily saxagliptin added to metformin is well tolerated and provides sustained glycaemic control over 102 weeks in patients with type 2 diabetes [abstract no. 132]. Diabetologia. 2009;52(Suppl. 1):S60.Google Scholar
- 27.Moses RG, Kalra S, Brook D, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycemic control on metformin plus a sulfonylurea. Diabetes Obes Metab. doi: 10.1111/dom.12234 [Epub 9 Nov 2013].
- 33.Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–9.PubMedCrossRefGoogle Scholar
- 35.Chen R, Donovan M, Rusnak JM, et al. Saxagliptin used as monotherapy or in combination with other antihyperglycaemic agents does not significantly increase risk of hypoglycaemia [abstract no. 2082-PO]. In: 69th Annual Scientific Sessions of the American Diabetes Association; 5–9 Jun 2009; New Orleans.Google Scholar
- 39.Onglyza® (saxagliptin) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2013.Google Scholar